CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The MARVAX project aims to develop effective vaccines against the Marburg virus by using viral vector platforms. It focuses on enhancing immune responses through multiple Marburg virus antigens and evaluating their safety and efficacy in preclinical models, ultimately preparing for clinical trials.
The frequency, magnitude, and geographical range of Marburg virus disease outbreaks are expanding, with recent cases emerging in Equatorial Guinea and Tanzania.
Marburgviruses, listed among the WHO priority pathogens, have demonstrated their epidemic potential.
However, no licensed vaccines are available, and outbreaks continue to impose high morbidity and mortality burdens.
Vaccine candidates in the pipeline are based on the Marburg virus (MARV) glycoprotein (GP) as a single immunogen. MARVAX a…
BERNHARD-NOCHT-INSTITUT FUER TROPENMEDIZIN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Spain, PORRINO
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
Guests see up to 5 keywords.
